Eli Lilly Faces Price Competition as Novo Nordisk Announces Cuts

Analysts back Eli Lilly despite Novo Nordisk's 2027 price cuts for Wegovy & Ozempic, citing Lilly's strong pipeline, Q4 earnings beat, and new oral drug launch.

The pharmaceutical sector is bracing for intensified rivalry after Novo Nordisk, a key competitor, revealed plans for significant price reductions on its weight-loss medications in the United States. While this move creates near-term uncertainty, market analysts maintain a positive outlook for Eli Lilly and Company, citing its robust development pipeline and strong financial performance as critical buffers.

Analysts Reaffirm Confidence Amid Competitive Pressures

Market experts are largely dismissing the long-term threat posed by Novo Nordisk's pricing strategy. On February 25, analysts at RBC Capital Markets reiterated their "Outperform" rating on Eli Lilly's stock, setting a price target of $1,250. Their research suggests Lilly's obesity treatment portfolio is positioned to maintain market leadership through 2030. This confidence is underpinned by solid quarterly results. For Q4 2025, the company reported revenue of $19.3 billion, a 43% increase that surpassed market expectations. Earnings per share also beat estimates, coming in at $7.54.

Management's guidance for the full 2026 fiscal year projects earnings per share in the range of $33.50 to $35.00. The equity, which closed at €871.80 yesterday, has significantly outperformed its industry peers over the past six months.

Novo Nordisk's Strategic Price Reductions

The competitive landscape is shifting as Danish rival Novo Nordisk announced it will drastically lower U.S. prices for its flagship drugs, Wegovy and Ozempic, starting in January 2027. The cost of Wegovy is slated to drop by approximately 50%, with Ozempic seeing a reduction of more than one-third. Industry observers interpret this as a preemptive move to secure market share through aggressive pricing before additional rival therapies enter the market. The strategy directly challenges Eli Lilly, whose drug Zepbound has recently been gaining traction.

Eli Lilly's Countermeasures and Pipeline Strength

Eli Lilly is not without defenses against this competitive onslaught. The company is advancing innovations in drug delivery to strengthen its position. Recently, the U.S. Food and Drug Administration (FDA) approved a new "Multi-Dose KwikPen" for Zepbound, simplifying administration for patients.

Furthermore, clinical data supports the company's competitive stance. Studies conducted over 84 weeks indicate that rival products do not demonstrate superiority over Lilly's active ingredient, tirzepatide. Another pivotal asset is the oral weight-loss pill orforglipron, which is planned for launch this year and could substantially broaden the treatment portfolio.

The upcoming rollout of these oral medications is now seen as a crucial factor for the stock's trajectory, as their success in the market will be key before the competitor's price cuts take effect in 2027.